XenImmune Tests GBI SmartScale for Protein Production
XenImmune Therapeutics and GBI Biomanufacturing agreed to assess GBI's SmartScale system for producing XenImmune's AGF protein molecules.
Updated on Nov. 3, 2026 in Biotech
XenImmune Therapeutics, based in Cambridge, Massachusetts, and GBI Biomanufacturing have agreed to assess whether GBI's SmartScale manufacturing platform can produce XenImmune's AGF fusion protein molecules. The agreement was announced on November 3, 2026.
Why it matters
XenImmune is developing molecules designed to target tumors, and manufacturing approach affects how quickly and economically such materials can move toward clinical use. The collaboration reflects an effort to explore manufacturing methods that align with disciplined capital use.
SmartScale is described as a stable pool-based platform combining stable cell pools, deferred cloning, and single-use manufacturing that can deliver GMP material. Production can be run in shake flasks or bioreactors so manufacturing scale can be matched to material quantities, but no specific performance metrics were disclosed.
The players
XenImmune Therapeutics
XenImmune Therapeutics is a Cambridge, Massachusetts-based company developing a class of fusion protein molecules designed to target tumors.
GBI Biomanufacturing
GBI Biomanufacturing is a biomanufacturing company that offers the SmartScale stable pool-based manufacturing platform.
The details
XenImmune is developing fusion protein molecules, called AGF molecules, that are designed to paint cancer cell surfaces with foreign blood group sugars or antigens. GBI Biomanufacturing will assess its SmartScale system to determine whether it can support production of these molecules.
Timeline
November 3, 2026: XenImmune and GBI announced the agreement to assess SmartScale.
The Tech Race
GBI states that SmartScale aligns with the FDA's Operation TrialBlazer initiative, which aims to accelerate clinical trial development. The platform's stable cell pools and single-use manufacturing reflect a broader push in biomanufacturing toward faster, more streamlined CMC development.
For patients, the outcome of manufacturing assessments like this one shapes how quickly experimental cancer therapies can reach clinical trials. The announcement itself does not change access to any product today.
The takeaway
Manufacturing choices made early in development can influence how efficiently a therapy moves toward trials, making platform assessments like this one worth watching for readers following biotech progress.
Further reading
Explore more Biotech developments shaping drug manufacturing.
Source note: This article includes information reported by The Manila times.
